Sensei Biotherapeutics Reports Full-Year 2025 Results, Advances PIKTOR Following Faeth Acquisition and $200 Million Financing
Sensei Biotherapeutics, has reported its financial results for the full year ended December 31, 2025, while also providing a comprehensive corporate update highlighting major strategic developments, including the acquisition of Faeth Therapeutics and a concurrent $200 million private placement financing. These milestones mark a significant turning point for the company as it sharpens its focus on advancing its lead oncology program, PIKTOR, into later-stage clinical development.
The acquisition of Faeth Therapeutics has added PIKTOR, an investigational, proprietary, all-oral combination therapy, to Sensei’s pipeline as its lead clinical asset. Alongside this strategic transaction, the company secured a substantial private placement that, combined with its existing cash reserves, is expected to fund operations through key upcoming clinical milestones.
Strategic Transformation and Pipeline Focus
With the integration of Faeth Therapeutics, Sensei Biotherapeutics has repositioned itself to prioritize targeted cancer therapies addressing critical signaling pathways. PIKTOR is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway—a key driver of tumor growth and survival in many cancers. Specifically, the therapy combines serabelisib, a PI3K-alpha inhibitor, with sapanisertib, a dual mTORC1/2 inhibitor, offering a multi-pronged mechanism of action.
This dual-targeting approach is intended to overcome limitations associated with single-node inhibition strategies, which often result in incomplete pathway suppression and therapeutic resistance. Early data suggest that PIKTOR may deliver more comprehensive pathway inhibition while maintaining a manageable tolerability profile.
Christopher Gerry, President and General Counsel of Sensei Biotherapeutics, emphasized the company’s strategic progress over the past year. He noted that 2025 was characterized by disciplined execution and a clear focus on repositioning the company for long-term success. With the addition of Faeth and new capital infusion, Sensei is entering 2026 with a defined roadmap centered on clinical advancement.
Clinical Development Plans for PIKTOR
Sensei is advancing PIKTOR through multiple clinical studies targeting solid tumor indications with high unmet medical need. The company is currently conducting a Phase 2 trial (Study FTH-PIK-201) evaluating the therapy in patients with advanced endometrial cancer. Topline data from this study are expected by the end of 2026.
In parallel, Sensei plans to initiate a Phase 1b trial (Study FTH-PIK-101) in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer. This study is also anticipated to generate initial results by year-end 2026.
Beyond these primary indications, the company is exploring additional opportunities to expand PIKTOR’s clinical utility into other tumor types, including ovarian and lung cancers. These expansion opportunities reflect the broad relevance of the PI3K/AKT/mTOR pathway across multiple malignancies.
Anand Parikh, Chief Operating Officer of Sensei Biotherapeutics, highlighted the potential of PIKTOR to address significant gaps in current treatment options. He pointed out that existing therapies targeting this pathway often face challenges related to efficacy and tolerability, and early findings suggest that PIKTOR could offer a differentiated profile.
Financial Performance Overview
Sensei Biotherapeutics reported a streamlined cost structure and improved financial efficiency for the full year 2025, reflecting ongoing efforts to align resources with its revised strategic priorities.
Cash Position
As of December 31, 2025, the company held cash, cash equivalents, and marketable securities totaling $21.2 million, compared to $41.3 million at the end of 2024. While this represents a year-over-year decrease, the recently completed $200 million private placement is expected to significantly strengthen the company’s liquidity position moving forward and support its clinical development plans.
Research and Development Expenses
Research and development (R&D) expenses for 2025 were $11.0 million, down from $18.6 million in 2024. This reduction was primarily driven by lower spending across several areas, including personnel costs, laboratory supplies, facility expenses, clinical trial activities, and manufacturing. The decrease reflects the company’s strategic restructuring and prioritization of key programs.
General and Administrative Expenses
General and administrative (G&A) expenses totaled $11.3 million in 2025, compared to $13.0 million in the prior year. The decline was largely due to reduced personnel-related costs. However, this was partially offset by increased restructuring expenses and higher consulting fees incurred during the year.
Net Loss
Sensei reported a net loss of $21.1 million for the full year 2025, a notable improvement compared to a net loss of $30.2 million in 2024. On a per-share basis, the net loss was $(16.72), compared to $(24.01) in the previous year. The reduced net loss reflects lower operating expenses and improved cost management.
The weighted-average number of common shares outstanding, both basic and diluted, was 1,260,772 for 2025, compared to 1,255,776 in 2024.
Operational Efficiency and Balance Sheet Highlights
The company’s total operating expenses declined significantly to $22.3 million in 2025 from $32.6 million in 2024. This reduction underscores Sensei’s efforts to streamline operations and focus resources on high-priority initiatives.
Loss from operations also improved to $22.3 million in 2025, compared to $32.6 million in the prior year. Additionally, total other income decreased to $1.2 million from $2.5 million year-over-year.
From a balance sheet perspective, Sensei reported total assets of $22.9 million as of December 31, 2025, down from $45.4 million at the end of 2024. Total liabilities decreased to $4.3 million from $7.0 million, while stockholders’ equity stood at $18.6 million, compared to $38.4 million in the previous year.
Cash and cash equivalents were $8.7 million, and marketable securities were $12.5 million as of year-end 2025.
Positioning for 2026 and Beyond
Looking ahead, Sensei Biotherapeutics is entering 2026 with a renewed strategic focus and strengthened financial backing. The combination of the Faeth acquisition and the $200 million private placement provides the company with the resources needed to advance PIKTOR through critical clinical milestones.
The anticipated data readouts from the Phase 2 endometrial cancer trial and the initiation of the Phase 1b breast cancer study represent key inflection points that could significantly influence the company’s trajectory.
Moreover, the potential expansion of PIKTOR into additional cancer indications offers further upside and reinforces the company’s commitment to developing innovative therapies targeting fundamental cancer pathways.
Conclusion
Sensei Biotherapeutics’ 2025 results reflect a year of transformation, marked by strategic acquisitions, disciplined cost management, and a renewed focus on clinical development. With PIKTOR emerging as its lead asset and a strengthened financial position, the company is well-positioned to pursue its goal of delivering novel, effective treatments for patients with difficult-to-treat cancers.
As the company advances into 2026, investors and stakeholders will be closely watching upcoming clinical milestones that could validate PIKTOR’s potential and shape the next phase of Sensei’s growth.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. Following the acquisition of Faeth Therapeutics, Sensei’s lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. Sensei is also completing a Phase 1/2 trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Sensei intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD
